Poland· PL-100469603
Pylera
A bismuth subcitrate, tetracycline and metronidazole product containing bismuthi kalii subcitras + metronidazolum + tetracyclini hydrochloridum, registered in Poland by Procareplus Pharma S.A.. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Bismuth subcitrate, tetracycline and metronidazole is registered in 9 of 19 countries.
Countries holding a registration under ATC A02BD08 (bismuth subcitrate, tetracycline and metronidazole), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Bismuth subcitrate, tetracycline and metronidazole · ATC A02BD08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Bismuthi kalii subcitras + Metronidazolum + Tetracyclini hydrochloridum
- Manufacturer
- Procareplus Pharma S.A.
- Country
- Poland (PL)
- ATC code
- A02BD08
- ATC class
- Bismuth subcitrate, tetracycline and metronidazole
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991485566
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bismuth subcitrate, tetracycline and metronidazole in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBismuth Subcitrate Potassium, Metronidazole and Tetracycline HydrochloridePar Health USA, LLC
- CzechiaPYLERALaboratoires Juvisé Pharmaceuticals, Villeurbanne
- GermanyPyleraAllomedic Gmbh
- FinlandPyleraLaboratoires Juvise Pharmaceuticals
- SwitzerlandPylera 140 mg/125 mg/125 mg, HartkapselnMedius AG
- IrelandPylera 140 mg/125 mg/125 mg capsules, hardLaboratoires Juvise Pharmaceuticals
- SwedenPylera 140 mg/125 mg/125 mg Kapsel, hårdLaboratoires Juvise Pharmaceuticals
- FrancePYLERA 140 mg/125 mg/125 mg, géluleLABORATOIRES JUVISE PHARMACEUTICALS
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Pylera
- Belgium · Tryplera
- Bulgaria · Pylera
- Czechia · Pylera
- Germany · Pylera
- Denmark · Pylera
- Estonia · Pylera
- Spain · Pylera
- Finland · Pylera
- France · Pylera
- United Kingdom (Northern Ireland) · Pylera
- Ireland · Pylera
- Italy · Pylera
- Lithuania · Pylera
- Luxembourg · Tryplera
- Latvia · Pylera
- Malta · Pylera
- Norway · Pylera
- Portugal · Pylera
- Romania · Pylera
- Sweden · Pylera
- Slovakia · Pylera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/067dd2b1-ec05-4ef3-aeb3-4ea57c0b8c0b GET /v1/drugs/067dd2b1-ec05-4ef3-aeb3-4ea57c0b8c0b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "140 mg + 125 mg + 125 mg",
"packaging": "05909991485566 ¦ Rp ¦ 145335\n120 kaps.",
"substance": "Bismuthi kalii subcitras 140 mg + Metronidazolum 125 mg + Tetracyclini hydrochloridum 125 mg",
"common_name": "Bismuthi kalii subcitras + Metronidazolum + Tetracyclini hydrochloridum",
"pl_product_id": "100469603",
"pozwolenie_nr": "249/22",
"auth_procedure": "IR",
"authorisation_validity": "2027-06-07"
}See everything about bismuth subcitrate, tetracycline and metronidazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.